Financial Survey: Telomir Pharmaceuticals (NASDAQ:TELO) versus electroCore (NASDAQ:ECOR)

electroCore (NASDAQ:ECOR) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Earnings & Valuation

This table compares electroCore and Telomir Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
electroCore	$25.18 million	2.27	-$11.89 million	($1.71)	-4.18
Telomir Pharmaceuticals	N/A	N/A	-$16.53 million	($0.37)	-3.76

electroCore has higher revenue and earnings than Telomir Pharmaceuticals. electroCore is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares electroCore and Telomir Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
electroCore	-47.46%	-447.87%	-73.83%
Telomir Pharmaceuticals	N/A	-566.61%	-447.89%

Institutional & Insider Ownership

26.7% of electroCore shares are owned by institutional investors. 13.8% of electroCore shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

electroCore has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500. Comparatively, Telomir Pharmaceuticals has a beta of -0.49, suggesting that its stock price is 149% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for electroCore and Telomir Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
electroCore	1	0	2	0	2.33
Telomir Pharmaceuticals	1	0	1	1	2.67

electroCore currently has a consensus price target of $25.50, indicating a potential upside of 257.14%. Telomir Pharmaceuticals has a consensus price target of $15.00, indicating a potential upside of 979.14%. Given Telomir Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Telomir Pharmaceuticals is more favorable than electroCore.

Summary

electroCore beats Telomir Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

About electroCore

electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.